## Abstract This study assessed the futility of proceeding with a Phase 3 clinical trial of minocycline as a diseaseβmodifying treatment for Huntington's disease (HD). One hundred fourteen research participants with HD were randomized, 87 to minocycline (200 mg/d) and 27 to placebo. The change in T
Revisiting safety of minocycline as neuroprotection in Huntington's disease
β Scribed by Norman Reynolds
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 36 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
We studied whether combinations of botanical extracts enriched in either D 9 -tetrahydrocannabinol (D 9 -THC) or cannabidiol (CBD), which are the main constituents of the cannabis-based medicine Sativex, provide neuroprotection in rat models of Huntington's disease (HD). We used rats intoxicated wit
## Abstract A semi professional marathon runner at risk for Huntington's disease (HD) (43 CAG repeats) developed signs of a slowly progressive myopathy with exerciseβinduced muscle fatigue, pain, elevated creatine kinase level, and worsening of his running performance many years before first signs